The structure-function relationship of disulfide bonds in etanercept

[1]  anonymous,et al.  Comprehensive review , 2019 .

[2]  H. Schlüter,et al.  Structural and In Vitro Functional Comparability Analysis of Altebrel™, a Proposed Etanercept Biosimilar: Focus on Primary Sequence and Glycosylation , 2019, Pharmaceuticals.

[3]  B. Jones,et al.  The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal , 2018, The AAPS Journal.

[4]  V. Strand,et al.  The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar , 2017, Current medical research and opinion.

[5]  Sheng‐yu Huang,et al.  Evaluation of disulfide scrambling during the enzymatic digestion of bevacizumab at various pH values using mass spectrometry. , 2016, Biochimica et biophysica acta.

[6]  Wei Zhang,et al.  Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept , 2016, mAbs.

[7]  A. Offidani,et al.  Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. , 2016, Current drug safety.

[8]  Zsombor Zrubka,et al.  Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents , 2016, Current medical research and opinion.

[9]  G. Lee,et al.  Purification of TNFR-Fc produced in recombinant CHO cells: Characterization of product-related impurities , 2015 .

[10]  알프레드 루프레히터,et al.  Quantification of misfolded tnfr2:fc , 2015 .

[11]  Tak W. Mak,et al.  Regulation of tumour necrosis factor signalling: live or let die , 2015, Nature Reviews Immunology.

[12]  Devharsh Trivedi,et al.  Overview and Applications , 2015 .

[13]  L. Sedger,et al.  TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. , 2014, Cytokine & growth factor reviews.

[14]  Markus F. Neurath,et al.  Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.

[15]  Mohammed Shameem,et al.  Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications , 2014, mAbs.

[16]  Ying Qing Yu,et al.  N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. , 2014, Analytical chemistry.

[17]  C. Schneider,et al.  Biosimilars in rheumatology: the wind of change , 2013, Annals of the rheumatic diseases.

[18]  B. Aggarwal,et al.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. , 2012, Blood.

[19]  Hongcheng Liu,et al.  Disulfide bond structures of IgG molecules , 2012, mAbs.

[20]  Martin Schiestl,et al.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.

[21]  Y. Yoshioka,et al.  Solution of the Structure of the TNF-TNFR2 Complex , 2010, Science Signaling.

[22]  D. Ouellette,et al.  Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule. , 2010, Analytical biochemistry.

[23]  Richard M. Johnson.  Guideline on similar biological medicinal products , 2010 .

[24]  M. Feldmann,et al.  Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[25]  Thomas M. Dillon,et al.  Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass* , 2008, Journal of Biological Chemistry.

[26]  Xu-Rong Jiang,et al.  Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. , 2008, Journal of pharmaceutical sciences.

[27]  P. Tak,et al.  Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.

[28]  B. Hazleman,et al.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution , 2007, Postgraduate Medical Journal.

[29]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[30]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[31]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[32]  C. Laurent.  Live or let die? , 1992, Nursing times.

[33]  M P Mitchell,et al.  The wind of change. , 1973, The Jamaican nurse.

[34]  L. S. King.  The medical revolution. , 1960, Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical School.